BLRX Stock Price History and Quote Analysis Insights for Investors

NASDAQ : BLRX

BioLineRx Ltd.

$0.25

-0.0006-0.24%

At Close 4:00 PM

$0.26

0.01+4.01%

Pre-Market 09:24 AM

71.42

BESG ScoreESG Rating

profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Stock Price Today

BioLineRx Ltd. (BLRX) stock declined over -0.24%, trading at $0.25 on NASDAQ, down from the previous close of $0.25. The stock opened at $0.26, fluctuating between $0.24 and $0.27 in the recent session.

Stock Snapshot

0.25

Prev. Close

0.26

Open

21.23M

Market Cap

85.11M

Number of Shares

0.2424

Day Low

0.2655

Day High

-0.83

P/E Ratio

99.44%

Free Float in %

-0.3

EPS (TTM)

0.18

Book Value

-0.32

Cash Flow per Share

1.38M

Volume

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 09, 2024	0.26	0.27	0.24	0.25	1.38M
Dec 06, 2024	0.27	0.27	0.23	0.25	1.21M
Dec 05, 2024	0.27	0.28	0.25	0.25	1.16M
Dec 04, 2024	0.29	0.29	0.26	0.27	1.34M
Dec 03, 2024	0.29	0.30	0.27	0.28	572.23K
Dec 02, 2024	0.30	0.30	0.27	0.29	1.4M
Nov 29, 2024	0.30	0.30	0.29	0.30	783.63K
Nov 27, 2024	0.28	0.30	0.27	0.29	1.35M
Nov 26, 2024	0.30	0.30	0.28	0.28	2.13M
Nov 25, 2024	0.29	0.29	0.25	0.27	6.69M
Nov 22, 2024	0.32	0.32	0.26	0.28	5.97M
Nov 21, 2024	0.43	0.43	0.32	0.32	10.48M
Nov 20, 2024	0.53	0.57	0.52	0.55	368.12K
Nov 19, 2024	0.47	0.55	0.47	0.54	1.02M
Nov 18, 2024	0.49	0.49	0.44	0.46	475.97K
Nov 15, 2024	0.48	0.48	0.45	0.48	345.84K
Nov 14, 2024	0.45	0.48	0.44	0.46	411.5K
Nov 13, 2024	0.43	0.46	0.43	0.45	402.3K
Nov 12, 2024	0.43	0.45	0.43	0.43	400.2K
Nov 11, 2024	0.44	0.46	0.43	0.45	367.37K

Contact Details

Hevel Modi'in, 7177871

Israel

Website: https://www.biolinerx.comContact: 972 864 29100

About Company

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Frequently Asked Questions

What is the current BioLineRx Ltd. (BLRX) stock price?

BioLineRx Ltd. (NASDAQ: BLRX) stock price is $0.25 in the last trading session. During the trading session, BLRX stock reached the peak price of $0.27 while $0.24 was the lowest point it dropped to. The percentage change in BLRX stock occurred in the recent session was -0.24% while the dollar amount for the price change in BLRX stock was -$0.00.

BLRX's industry and sector of operation?

The NASDAQ listed BLRX is part of Biotechnology industry that operates in the broader Healthcare sector. BioLineRx Ltd. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of BLRX?

Dr. Abi Vainstein-Haras M.D.
Chief Medical Officer
Mr. Adam Janoff Esq.
Gen. Counsel & Head of Compliance
Ms. Mali Zeevi CPA, CPA
Chief Financial Officer
Advocate Norman Kotler
Internal Enforcement Officer, Gen. Counsel and Corporation Sec.
Ms. Holly W. May M.B.A.
Pres of BioLineRx USA
Mr. Raziel Fried
Treasurer & Budgetary Control Director
Dr. Ella Sorani
Chief Devel. Officer
Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA
Chief Executive Officer
Mr. John Lacey
Head of Corporation Communications & Investor Relations
Ms. Jael Birenberg M.Sc.
Senior Director & Head of RA, QA and PhV
Ms. Tsipi Keren-Lehrer B.Sc., L.L.B.
Head of BD & Strategic Advisor
Ms. Liron Shemesh-Darvish M.B.A., Ph.D.
Senior Director & Head of Preclinical Devel.

How BLRX did perform over past 52-week?

BLRX's closing price is 8.44% higher than its 52-week low of $0.23 where as its distance from 52-week high of $1.82 is -86.3%.

How many employees does BLRX have?

Number of BLRX employees currently stands at 79.

Link for BLRX official website?

Official Website of BLRX is: https://www.biolinerx.com

How do I contact BLRX?

BLRX could be contacted at phone 972 864 29100 and can also be accessed through its website. BLRX operates from Modi’in Technology Park, Hevel Modi'in, 7177871, Israel.

How many shares of BLRX are traded daily?

BLRX stock volume for the day was 1.38M shares. The average number of BLRX shares traded daily for last 3 months was 824.05K.

What is the market cap of BLRX currently?

The market value of BLRX currently stands at $21.23M with its latest stock price at $0.25 and 85.11M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

Employees	79
Beta	0.87
Sales or Revenue	$4.80M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology